Resolution

Gemeinsamer Bundesausschuss

of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V – Ingenol Mebutate (Repeal of the Resolution of 21 February 2019)

of 20 August 2020

At its session on 20 August 2020, the Federal Joint Committee (G-BA) resolved to amend the Directive on the Prescription of Medicinal Products in SHI-accredited Medical Care (Pharmaceuticals Directive, AM-RL) in the version dated 18 December 2008/22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended on DD Month YYYY (Federal Gazette, BAnz AT DD MM YYYY Bx), as follows:

I. The findings regarding the benefit assessment of the active ingredient ingenol mebutate in Annex XII to the AM-RL, as amended by the resolution of 21 February 2019 are hereby repealed.

II. The resolution will enter into force with effect from the day of its publication on the internet on the website of the G-BA on 20 August 2020.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 20 August 2020

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken